The last year (and particularly the last few months) of the Biden Administration brought a flurry of activity from the Federal Trade Commission ...
Exelixis, Inc. (NASDAQ:EXEL) authorized repurchasing up to an additional $500 million of the company’s common stock before December 31, 2025. Exelixis plans to complete the $500 million stock ...
Hosted on MSN2h
NICE green lights two blood cancer therapies for NHS useBMS’ Breyanzi and Amgen’s Blincyto will now be available to patients in England with certain types of blood cancer.
Bristol-Myers Squibb released financial results for Q4 2024. Check out why I am upgrading BMY stock's rating from 'Buy' to ...
With the robust demand for personalized medicines and the growing adoption of digital technology, the precision medicine ...
With 2025 underway, the AFS Health Care team highlights some of the most pressing legal issues facing the health care industry this year.
Bernstein analyst Courtney Breen maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report) yesterday and set a price target of ...
Hosted on MSN14h
Eli Lilly Remains JPMorgan's Top Biopharma Pick For 2025, But Gilead And Bristol Myers Also Gain Praise — Is Retail On Board?JPMorgan is sticking with Eli Lilly (LLY) as its top biopharma pick for 2025, while also highlighting Gilead Sciences (GILD) ...
Additional data from CheckMate 274 showed that adjuvant nivolumab benefits patients with muscle-invasive bladder cancer with ...
Shares of Bristol Myers Squibb Co. BMY rose 1.47% to $55.79 Thursday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index SPX falling 0.43% to ...
Bristol Myers Squibb Co. said Cari Gallman, the company’s executive vice president for corporate affairs, will become its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback